Quality & Performance Report

Author: John Adler Sponsor: Chief Executive Date: IFPIC + QAC 17th December 2015

Executive Summary from CEO

Context

It has been agreed that I will provide a summary of the issues within the Q&P Report that I feel should particularly be brought to the attention of EPB, IFPIC and QAC. This complements the Exception Reports which are triggered automatically when identified thresholds are met.

Questions

- 1. What are the issues that I wish to draw to the attention of the committee?
- 2. Is the action being taken/planned sufficient to address the issues identified? If not, what further action should be taken?

Conclusion

Good News: RTT - The RTT incomplete target remains compliant. This is particularly good in the light of rising referrals. The NHS has failed this target as a whole which makes our compliance increasingly rare. **DTOC** - Delayed transfers of care continues to remain well within the tolerance which reflects the good work that continues across the system in this area. **MRSA** - remains at zero for the year. **Annual appraisals rates** – continue to improve for the 3rd month in a row. **C DIFF** – within monthly and year to date trajectory. This continues to be closely monitored in respect of antibiotic prescribing controls and cleaning standards. **Pressure Ulcers** - there were zero avoidable **Grade 4** pressure ulcers reported for the 8th consecutive month. **Fractured NOF** – performance much improved at 72.5% after the dip in performance last month.

Bad News:

ED 4 hour performance- was 81.7% which for now the fourth month in a row was worse than the corresponding month the year before. It has slipped to 90.0% year to date. This continues to be primarily driven by record ED attendances and emergency admissions but has also been contributed to by staffing issues. Further detail is in the Chief Operating Officer's Emergency Care report. **Referral to Treament 52+ week waits.** We are struggling to bring down these long waits due to an inability to recruit additional consultants or to find capacity at other providers. This is an issue of national significance due to the numbers involved. **Diagnostics** - There has been slight improvement in month with performance estimated at 6.5%. This is behind the planned recovery trajectory and should be further explored by IFPIC. **Cancelled operations** and **patients rebooked within 28 days** - were both non-compliant, predominantly due to increased adult and children emergencies cancelling last minute cancellations. **Cancer Standards -** the 62

day backlog remains high. A Remedial Action Plan has been submitted to commissioners with a revised compliance date of June 2016, although we are aiming for March 2016. **Ambulance Handover** – again a very challenging month for Ambulance handovers, directly linked to the emergency demand referenced above. This remains a serious risk in the system.

Input Sought

I recommend that the Committee:

- Commends the positive achievements noted under Good News
- Note the areas of Bad News and consider if the actions being taken are sufficient.

For Reference

Edit as appropriate:

1. The following objectives were considered when preparing this report:

| Safe, high quality, patient centred healthcare |
|---|
| Effective, integrated emergency care |
| Consistently meeting national access standards |
| Integrated care in partnership with others |
| Enhanced delivery in research, innovation & ed' |
| A caring, professional, engaged workforce |
| Clinically sustainable services with excellent facilities |
| Financially sustainable NHS organisation |
| Enabled by excellent IM&T |

[Yes /No /Not applicable] [Yes /No /Not applicable] [Yes /No /Not applicable] [Yes /No /Not applicable] [Yes /No /Not applicable] [Yes /No /Not applicable] [Yes /No /Not applicable] [Yes /No /Not applicable]

2. This matter relates to the following governance initiatives:

| Organisational Risk Register | [Yes /No /Not applicable] |
|------------------------------|--|
| Board Assurance Framework | [Yes / No /Not applicable] |

3. Related Patient and Public Involvement actions taken, or to be taken: Not Applicable

4. Results of any Equality Impact Assessment, relating to this matter: Not Applicable

5. Scheduled date for the next paper on this topic: 17th December 2015

Caring at its best

University Hospitals of Leicester

Quality and Performance Report

November 2015

One team shared values



CONTENTS

 Page 2
 Introduction and Performance Summary

 Page 3
 New Indicators

 Indicators Removed
 Indicators

Indicators where reporting methodology has been changed

Dashboards

- Page 4 Safe Domain Dashboard
- Page 5 Caring Domain Dashboard
- Page 6 Well Led Domain Dashboard
- Page 7 Effective Domain Dashboard
- Page 8 Responsive Domain Dashboard
- Page 9 Responsive Domain Cancer Dashboard
- Page 10 Compliance Forecast for Key Responsive Indicators
- Page 11 Research & Innovation UHL

Exception Reports

- Page 12 Emergency Readmissions
- Page 13 52 Week Breaches Incompletes
- Page 14 6 Week Diagnostic Test Waiting Times
- Page 15 Cancelled patients not offered a date with 28 days of the cancellations UHL
- Page 16 NHS e-Referral System (formerly known as Choose and Book)
- Page 17 Ambulance Handovers
- Page 18 Cancer Waiting Times Performance
- Page 19 Cancer Patients Breaching 104 Days

UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST

- REPORT TO: INTEGRATED FINANCE, PERFORMANCE AND INVESTMENT COMMITTEE QUALITY ASSURANCE COMMITTEE
- DATE: 17th DECEMBER 2015
- REPORT BY: ANDREW FURLONG, INTERIM MEDICAL DIRECTOR RICHARD MITCHELL, DEPUTY CHIEF EXECUTIVE/CHIEF OPERATING OFFICER JULIE SMITH, CHIEF NURSEjohn LOUISE TIBBERT, DIRECTOR OF WORKFORCE AND ORGANISATIONAL DEVELOPMENT
- SUBJECT: NOVEMBER 2015 QUALITY & PERFORMANCE SUMMARY REPORT

1.0 Introduction

The following report provides an overview of TDA/UHL key quality and performance metrics and escalation reports where applicable.

2.0 <u>Performance Summary</u>

| Domain | Page Number | Number of Indicators | Indicators with target to be confirmed | Number of Red Indicators this month |
|-------------------|----------------|-------------------------|---|---|
| Safe | 4 | 22 | 7 | 0 |
| Caring | 5 | 10 | 3 | 0 |
| Well Led | 6 | 18 | 6 | 2 |
| Effective | 7 | 16 | 3 | 1 |
| Responsive | 8 | 17 | 2 | 9 |
| Responsive Cancer | 9 | 9 | 0 | 5 |
| Research – UHL | 11 | 6 | 6 | 0 |
| Total | | 98 | 38 | 17 |

3.0 <u>New Indicators</u>

None.

4.0 Indicators removed

None.

5.0 Indicators where reporting methodology/thresholds have changed

None.



| | KPI Ref Indicators | Board Director | Lead Officer | 15/16 Target | Target Set by | Red RAG/ Exception Report Threshold (ER) | 13/14 Outturn | 14/15 Outturn | Sep-14 | Oct-14 | Nov-14 | Dec-14 | Jan-15 | Feb-15 | Mar-15 | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | YTD |
|----------|--|-------------------|-----------------|------------------------------|------------------|--|------------------|------------------|--------------------|--------|--------|--------|----------|--------------------|------------|--------|----------|---------|--------|--------|--------|--------|--------|--------------------|
| | S1 Clostridium Difficile | JS | DJ | 61 | TDA | Red if >mthly threshold / ER if Red or Non compliance with cumulative target | 66 | 73 | 5 | 7 | 7 | 11 | 7 | 5 | 7 | 3 | 1 | 4 | 4 | 6 | 6 | 6 | 4 | 34 |
| | S2a MRSA Bacteraemias (All) | JS | DJ | 0 | TDA | Red if >0 ER if >0 | 3 | 6 | 1 | 1 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | S2b MRSA Bacteraemias (Avoidable) | JS | DJ | 0 | UHL | Red if >0 ER if >0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | S3 Never Events | JS | MD | 0 | TDA | Red if >0 in mth ER = in mth >0 | 3 | 3 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| | S4 Serious Incidents | JS | MD | Not within Highest Decile | TDA | TBC | 60 | 41 | 3 | 4 | 2 | 4 | 3 | 2 | 1 | 2 | 8 | 1 | 5 | 3 | 5 | 3 | 4 | 31 |
| | S5a Proportion of reported safety incidents per 1000 beddays | JS | MD | TBC | TDA | TBC | 37.5 | 39.1 | 41.8 | 38.9 | 40.3 | 40.4 | 35.0 | 38.2 | 36.3 | 34.6 | 37.3 | 39.6 | 39.9 | 37.1 | 33.6 | 38.7 | 34.6 | 36.9 |
| - | S5b Proportion of reported safety incidents that are harmful | JS | MD | Not within Highest Decile | TDA | TBC | 2.8% | 1.9% | 2.2% | | 1.4% | | | 2.3% | | | 2.2% | | | 1.9% | | | | 2.1% |
| - | S6 Overdue CAS alerts | JS | MD | 0 | TDA | Red if >0 in mth ER = in mth >0 | 2 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | S7 RIDDOR - Serious Staff Injuries | JS | MD | FYE = <40 | UHL | Red / ER if non compliance with cumulative target | 47 | 24 | 1 | 2 | 2 | 1 | 0 | 3 | 2 | 0 | 6 | 0 | 0 | 2 | 3 | 7 | 2 | 20 |
| a | S8a Safety Thermometer % of harm free care (all) | JS | ЕМ | Not within Lowest Decile | TDA | Red if <92% ER = in mth <92% | 93.6% | 94.1% | <mark>93.9%</mark> | 94.9% | 93.3% | 94.1% | 95.0% | <mark>92.1%</mark> | 93.6% | 93.7% | 94.3% | 95.6% | 94.6% | 93.2% | 94.0% | 93.5% | 94.2% | <mark>94.2%</mark> |
| Safe | S8b Safety Thermometer % number of new harms | JS | ЕМ | Not within Lowest Decile | TDA | TBC | | TDA cator | 2.5% | 2.3% | 3.3% | 2.4% | 2.5% | 3.2% | 2.7% | 2.2% | 2.6% | 2.1% | 1.9% | 3.1% | 2.4% | 2.6% | 2.7% | 2.4% |
| | S9 % of all adults who have had VTE risk assessment on adm to hosp | AF | SH | 95% or above | TDA | Red if <95% ER if in mth <95% | 95.3% | 95.8% | 96.2% | 95.4% | 95.5% | 95.0% | 96.3% | 96.2% | 95.6% | 96.0% | 96.0% | 96.5% | 96.2% | 96.5% | 96.1% | 95.7% | 96.0% | 96.1% |
| | S10 All Medication errors causing serious harm | AF | CE | 0 | TDA | Red if >0 in mth ER if in mth >0 | | | | | | NE | EW TDA I | NDICATO | OR - DEFII | | D BE CO | NFIRMED |) | | | | | |
| | S11 All falls reported per 1000 bed stays for patients >65years | JS | HL | <7.1 | QC | Red if >8.4 ER if 2 consecutive reds | 7.1 | 6.9 | 5.9 | 6.4 | 7.5 | 6.9 | 7.1 | 6.7 | 6.3 | 5.7 | 5.8 | 5.0 | 5.7 | 5.7 | 4.1 | 5.2 | 4.3 | 5.2 |
| - | S12 Avoidable Pressure Ulcers - Grade 4 | JS | мс | 0 | QS | Red / ER if Non compliance with monthly target | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | S13 Avoidable Pressure Ulcers - Grade 3 | JS | мс | <=6 a month | QS | Red / ER if Non compliance with monthly target | 71 | 69 | 6 | 4 | 6 | 7 | 5 | 9 | 6 | 3 | 0 | 4 | 1 | 4 | 1 | 1 | 1 | 15 |
| | S14 Avoidable Pressure Ulcers - Grade 2 | JS | мс | <=8 a month | QS | Red / ER if Non compliance with monthly target | 120 | 91 | 4 | 8 | 13 | 11 | 7 | 5 | 9 | 10 | 8 | 8 | 8 | 10 | 11 | 5 | 4 | 64 |
| - | S15 Compliance with the SEPSIS6 Care Bundle | AF | JP | All 6 >75% by Q4 | QC | Red/ER if Non compliance with Quarterly target | 27.0% | <65% | >=60% | | <65% | | | <75% | | | | | AUDIT | IN PRO | GESS | | | |
| | S16 Maternal Deaths | AF | IS | 0 | UHL | Red or ER if >0 | 3 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | S17 Emergency C Sections (Coded as R18) | IS | EB | Not within Highest Decile | TDA | Red / ER if Non compliance with monthly target | 16.1% | 16.5% | 17.4% | 18.1% | 17.4% | 16.2% | 17.7% | 15.5% | 15.8% | 15.3% | 18.8% | 15.8% | 15.8% | 15.2% | 16.5% | 20.9% | 19.7% | 17.3% |
| | S18 Potential under reporting of patient safety indicators | JS | MD | Not within Highest Decile | TDA | Red / ER if Non compliance with monthly target | | | | | | NE | EW TDA I | NDICATO | DR - DEFI | | D BE COM | NFIRMED | | | | | | |
| | S19 Potential under reporting of patient safety indicators resulting in death or severe harm | JS | MD | Not within Highest Decile | TDA | Red / ER if Non compliance with monthly target | | | | | | NE | EW TDA I | NDICATO | DR - DEFII | | D BE COM | NFIRMED | | | | | | |



| | KPI Ref | Indicators | Board Director | Lead Officer | 15/16 Target | Target Set by | Red RAG/ Exception Report Threshold (ER) | 13/14 Outturn | 14/15 Outturn | Sep-14 | Oct-14 | Nov-14 | Dec-14 | Jan-15 | Feb-15 | Mar-15 | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | YTD |
|------|---------|--|-------------------|-----------------|------------------------------|------------------|---|------------------|------------------|---------|--------|----------------------------|--------|----------|---------|-----------|-----------|-------------------|---------|--------|--------|--------|--------|--------|-------|
| | C1 | Inpatients (Including Daycases) Friends and Family Test - % positive | JS | HL | Q1 95% Q2/3 96% Q4 97% | QC | Red if <95% ER if 2 mths Red | New Indicator | 96% | 97% | 96% | 96% | 96% | 96% | 96% | 97% | 96% | 96% | 97% | 96% | 97% | 97% | 97% | 96% | 96% |
| | C2 | A&E Friends and Family Test - % positive | JS | HL | Q1 95% Q2/3 96% Q4 97% | QC | Red if <94% ER if 2 mths Red | New Indicator | 96% | 95% | 96% | 96% | 96% | 96% | 96% | 97% | 96% | 96% | 96% | 96% | 97% | 95% | 95% | 97% | 96% |
| | C3 | Outpatients Friends and Family Test - % positive | JS | HL | Q1 95% Q2/3 96% Q4 97% | QC | Red if <90% ER if 2 mths Red | | N | EW METH | | GVEOR | | | | | 94% | <mark>94</mark> % | 93% | 91% | 93% | 93% | 93% | 92% | 93% |
| b | C4 | Daycase Friends and Family Test - % positive | JS | HL | Q1 95% Q2/3 96% Q4 97% | QC | Red if <95% ER if 2 mths Red | | IN. | | IODOLO | arron | UALUUL | ATING /6 | | | 96% | 97% | 97% | 98% | 98% | 97% | 98% | 98% | 97% |
| arin | C5 | Maternity Friends and Family Test - % positive | JS | HL | Q1 95% Q2/3 96% Q4 97% | QC | Red if <94% ER if 2 mths Red | | 96% | 94% | 96% | 97% | 95% | 97% | 96% | 96% | 95% | 96% | 95% | 95% | 96% | 95% | 95% | 95% | 95% |
| C | C6 | Friends & Family staff survey: % of staff who would recommend the trust as place to receive treatment | LT | LT | Not within Lowest Decile | TDA | TBC | New Indicator | 69.2% | | | FT not con Il Survey ca | | | 71.4% | | | 68.7% | | | 71.9% | | | | 70.3% |
| | C7a | Complaints Rate per 100 bed days | AF | MD | TBC | UHL | TBC | New Indicator | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| | C7b | Written Complaints Received Rate per 100 bed days | AF | MD | Not within Highest Decile | TDA | TBC | | | | | | NE | EW TDA I | NDICATO |)r - Defi | NITION TO | BE COM | NFIRMED | | | | | | |
| | C8 | Complaints Re-Opened Rate | AF | MD | <=12% | UHL | Red if >=15% ER if >=15% | New Indicator | 10% | 9% | 11% | 11% | 10% | 17% | 13% | 11% | 13% | 7% | 7% | 7% | 11% | 11% | 8% | 9% | 9% |
| | | Single Sex Accommodation Breaches (patients affected) | JS | HL | 0 | TDA | Red / ER if >0 | 2 | 13 | 0 | 0 | 5 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

| | KPI Ref | Indicators | Board Director | Lead Officer | 15/16 Target | Target Set by | Red RAG/ Exception Report Threshold (ER) | 13/14 Outturn | 14/15 Outturn | Sep-14 | Oct-14 | Nov-14 | Dec-14 | Jan-15 | Feb-15 | Mar-15 | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | YTD |
|--------|---------|---|-------------------|-----------------|-----------------------------|------------------|---|------------------|------------------|----------|--------|-------------------------|--------|-------------|----------|--------|------------------|------------------|------------------|--------|--------|--------|--------------------|------------------|------------------|
| | W1 | Inpatients Friends and Family Test - Coverage (Adults and Children) | JS | HL | 30% | TDA | Red if <26% ER if 2mths Red | NEW M | IETHODOI | .OGY FOF | | ATING CO | | E INCLUD | ES ADULT | rs and | 29.2% | 30.5% | 29.0% | 27.7% | 28.9% | 28.9% | 37.4% | 38.2% | 32.2% |
| | W2 | Daycase Friends and Family Test - Coverage (Adults and Children) | JS | HL | 20% | TDA | Red if <8% ER if 2 mths Red | NEW N | IETHODOI | .OGY FOF | | ATING CO | | EINCLUD | ES ADULT | rs and | 12.5% | 12.1% | 15.5% | 20.5% | 23.8% | 24.1% | 27.2% | 27.7% | 24.5% |
| | W3 | A&E Friends and Family Test - Coverage | JS | HL | 20% | TDA | Red if <10% ER if 2 mths Red | NEW N | IETHODOI | .OGY FOF | | ATING CO HILDREN | | EINCLUD | ES ADULT | rs and | 14.7% | 14.9% | 13.3% | 14.1% | 13.3% | 13.1% | 16.1% | 12.4% | 14.0% |
| | W4 | Outpatients Friends and Family Test - Coverage | JS | HL | Q1 3% Q2/3 4% Q4 5% | UHL | Red if <2.5% ER Qtrly | NEW N | IETHODOI | .OGY FOF | | ATING CO | | EINCLUD | ES ADULT | rs and | 1.3% | 1.6% | 1.2% | 1.2% | 1.4% | 1.4% | 1.5% | 1.5% | 1.4% |
| | W5 | Maternity Friends and Family Test - Coverage | JS | HL | 30% | UHL | Red if <26% ER if 2 mths Red | 25.2% | 28.0% | 18.7% | 15.8% | 21.7% | 22.1% | 25.8% | 46.5% | 40.2% | 32.3% | 35.8% | 32.6% | 25.6% | 30.5% | 27.9% | 27.2% | 38.8% | 31.3% |
| | W6 | Friends & Family staff survey: % of staff who would recommend the trust as place to work | LT | BK | Not within Lowest Decile | TDA | TBC | New Indicator | 54.2% | 53.7% | | FT not con Survey ca | | | 54.9% | | | 52.5% | | | 55.7% | | | | 54.0% |
| | W7a | Nursing Vacancies | JS | MM | 5% by Mar 16 | UHL | Separate report submitted to QAC | | V UHL CATOR | 6.7% | 6.7% | 6.4% | 6.0% | 6.3% | 5.5% | 6.5% | 8.5% | 8.0% | 7.3% | 8.7% | 8.9% | 8.5% | 7.1% | 7.6% | 7.6% |
| e d | W7b | Nursing Vacancies in ESM CMG | JS | MM | 5% by Mar 16 | UHL | Separate report submitted to QAC | | V UHL CATOR | 10.8% | 10.8% | 10.7% | 9.7% | 12.8% | 11.4% | 14.0% | 19.3% | 13.0% | 14.4% | 13.3% | 13.5% | 13.5% | 12.9% | 14.6% | 14.6% |
| e II L | W8 | Turnover Rate | LT | LG | Not within Lowest Decile | TDA | Red = 11% or above ER = Red for 3 Consecutive Mths | 10.0% | 11.5% | 10.3% | 10.8% | 10.7% | 10.3% | 10.1% | 10.1% | 11.5% | 10.4% | 10.5% | 10.5% | 10.6% | 10.4% | 10.4% | 10.2% | 9.9% | 9.9% |
| > | W9 | Sickness absence | LT | KK | 3% | UHL | Red if >4% ER if 3 consecutive mths >4.0% | 3.4% | 3.8% | 3.7% | 4.0% | 4.0% | 4.4% | 4.2% | 4.1% | 4.0% | 3.6% | 3.4% | 3.4% | 3.3% | 3.2% | 3.3% | 3.7% | | 3.4% |
| | W10 | Temporary costs and overtime as a % of total paybill | LT | LG | TBC | TDA | TBC | New Indicator | 9.4% | 8.5% | 9.5% | 9.0% | 9.8% | 10.5% | 9.8% | 11.5% | 10.7% | 10.2% | 11.0% | 10.8% | 11.1% | 9.9% | 10.5% | 10.5% | 10.4% |
| | W11 | % of Staff with Annual Appraisal | LT | BK | 95% | UHL | Red if <90% ER if 3 consecutive mths <90% | 91.3% | 91.4% | 89.7% | 91.8% | 92.3% | 92.5% | 90.9% | 91.0% | 91.4% | 90.1% | 88.7% | 89.0% | 89.1% | 88.8% | 90.0% | <mark>90.4%</mark> | 91.1% | 91.1% |
| | W12 | Statutory and Mandatory Training | LT | BK | 95% | UHL | TBC | 76% | 95% | 85% | 86% | 87% | 89% | 89% | 90% | 95% | <mark>93%</mark> | <mark>92%</mark> | <mark>92%</mark> | 91% | 91% | 91% | <mark>92%</mark> | <mark>92%</mark> | <mark>92%</mark> |
| | W13 | % Corporate Induction attendance | LT | BK | 95% | UHL | Red if <90% ER if 3 consecutive mths <90% | 94.5% | 100% | 98% | 98% | 98% | 100% | 99% | 100% | 97% | 97% | 97% | 98% | 100% | 97% | 98% | 98% | 97% | 97% |
| | W14a | DAY Safety staffing fill rate - Average fill rate - registered nurses/midwives (%) | JS | ММ | Not within Lowest Decile | TDA | TBC | | 91.2% | 91.6% | 92.9% | 91.3% | 92.7% | 94.3% | 91.8% | 91.0% | 93.6% | 90.3% | 91.2% | 90.3% | 90.2% | 90.5% | 91.4% | 87.2% | 90.6% |
| | W14b | DAY Safety staffing fill rate - Average fill rate - care staff (%) | JS | ММ | Not within Lowest Decile | TDA | TBC | New | 94.0% | 90.3% | 95.4% | 94.4% | 95.8% | 95.4% | 92.8% | 92.5% | 94.2% | 91.2% | 93.5% | 91.3% | 92.4% | 93.1% | 94.2% | 93.2% | 92.9% |
| | W14c | NIGHT Safety staffing fill rate - Average fill rate - registered nurses/midwives (%) | JS | ММ | Not within Lowest Decile | TDA | TBC | Indicator | 94.9% | 94.8% | 97.4% | 96.5% | 96.4% | 97.9% | 96.5% | 97.2% | 98.9% | 96.0% | 96.2% | 94.3% | 94.3% | 94.9% | 96.1% | 91.4% | 95.3% |
| | W14d | NIGHT Safety staffing fill rate - Average fill rate - care staff (%) | JS | ММ | Not within Lowest Decile | TDA | TBC | | 99.8% | 97.8% | 100.8% | 101.2% | 101.4% | 103.6% | 100.8% | 103.2% | 106.3% | 98.7% | 99.4% | 101.2% | 98.0% | 100.0% | 99.9% | 98.4% | 100.3% |

Safe Caring Well Led Effective Responsive Research

Safe Caring Well Led Effective Responsive Research

| | (PI Ref | Indicators | Board Director | Lead Officer | 15/16 Target | Target Set by | Red RAG/ Exception Report Threshold (ER) | 13/14 Outturn | 14/15 Outturn | Sep-14 | Oct-14 | Nov-14 | Dec-14 | Jan-15 | Feb-15 | Mar-15 | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | YTD |
|----------|---------|---|-------------------|-----------------|------------------------|------------------|---|-------------------------------|------------------|--------------------------|--------|------------------------------|--------|--------------|-----------------|-----------|--------|-----------------|---------|---------------|---------------|----------|--------|-----------------|-------|
| | E1 | Mortality - Published SHMI | AF | PR | Within Expected | TDA | Higher than Expected | 105 | 103 | 106 (Jan13- Dec13) | (A) | 105 pr13-Mar ⁻ | 14) | (J | 105 ul13-Jun | 14) | (0 | 103 ct13-Sep | o14) | (Ja | 99 n14-Dec | 14) | (Aj | 98 pr14-Mar1 | 15) |
| | E2 | Mortality - Rolling 12 mths SHMI (as reported in HED) Rebased | AF | PR | Within Expected | QC | Red if >expected ER if >Expected or 3 consecutive mths increasing SHMI >100 | 105 | 98 | 101 | 101 | 100 | 99 | 99 | 98 | 98 | 98 | 96 | 95 | 95 | Aw | aiting H | ED Upd | ate | 95 |
| | E3 | Mortality HSMR (DFI Quarterly) | AF | PR | Within Expected | TDA | Red if >expected ER if >Expected or 3 consecutive increasing mths >100 | 88 | 94 | 92 | | 93 | | | 93 | | | 85 | | | Awaiti | ng DFI L | Jpdate | | 85 |
| | | Mortality - Rolling 12 mths HSMR (Rebased Monthly as reported in HED) | AF | PR | Within Expected | QC | Red if >expected ER if >Expected or 3 consecutive increasing mths >100 | 99 | 94 | 95 | 95 | 94 | 94 | 95 | 95 | 94 | 94 | 94 | 93 | 93 | 93 | Awaitin | Ig HED | Jpdate | 93 |
| | E5 | Mortality - Monthly HSMR (Rebased Monthly as reported in HED) | AF | PR | Within Expected | QC | Red if >expected ER if >Expected or 3 consecutive increasing mths >100 | 91 | 94 | 97 | 95 | 88 | 95 | 99 | 98 | 86 | 83 | 96 | 99 | 85 | 88 | Awaitin | Ig HED | Jpdate | 90 |
| | | Mortality - HSMR ALL Weekend Admissions - (DFI Quarterly) | AF | PR | Within Expected | QC | Red if >expected ER if >Expected or 3 consecutive increasing mths >100 | 96 | 100 | 99 | | 96 | | | 106 | | | 93 | | | Awaiti | ng DFI L | Jpdate | | 93 |
| ve | E7 | Crude Mortality Rate Emergency Spells | AF | PR | Within Upper Decile | TDA | ТВС | 2.5% | 2.4% | 2.3% | 2.1% | 2.3% | 3.0% | 3.1% | 2.7% | 2.4% | 2.1% | 2.0% | 2.3% | 1.8% | 2.0% | 2.2% | 2.4% | 2.1% | 2.1% |
| Effectiv | E8 | Deaths in low risk conditions (Risk Score) | AF | PR | Within Expected | TDA | Red if >expected ER if >Expected or 3 consecutive increasing mths >100 | 94 | 80 | 58 | 111 | 59 | 84 | 100 | 86 | 74 | 120 | 20 | 37 | 38 | 102 | Awaitin | Ig HED | Update | 62 |
| ш | | Emergency readmissions within 30 days following an elective or emergency spell | AF | JJ | Within Expected | UHL | Red if >7% ER if 3 consecutive mths >7% | 7.9% | 8.5% | 8.4% | 8.6% | 8.9% | 9.1% | 8.2% | 8.5% | 8.5% | 9.2% | 9.1% | 9.0% | 8.8% | 8.9% | 8.7% | 9.0% | | 9.0% |
| | | No. of # Neck of femurs operated on 0-35 hrs - Based on Admissions | AF | RP | 72% or above | QS | Red if <72% ER if 2 consecutive mths <72% | 65.2% | 61.4% | 68.6% | 69.6% | 59.4% | 57.3% | 57.9% | 67.2% | 61.5% | 55.7% | 42.6% | 70.1% | 60.3 % | 78.1% | 72.0% | 60.0% | 72.5% | 64.1% |
| | E11 | Stroke - 90% of Stay on a Stroke Unit | RM | IL | 80% or above | QS | Red if <80% ER if 2 consecutive mths <80% | 83.2% | 81.3% | 83.2% | 69.4% | 72.4% | 74.3% | 82.5% | 87.6% | 81.5% | 83.7% | 84.5% | 84.5% | 85.7% | 90.9% | 86.9% | 81.1% | | 85.4% |
| | | Stroke - TIA Clinic within 24 Hours (Suspected High Risk TIA) | RM | IL | 60% or above | QS | Red if <60% ER if 2 consecutive mths <60% | 64.2% | 71.2% | 72.7% | 67.8% | 69.0% | 83.5% | 80.6% | 64.0% | 77.3% | 86.3% | 79.6% | 72.0% | 78.9% | 80.2% | 88.1% | 73.3% | 67.1% | 78.0% |
| | E13 | Published Consultant Level Outcomes | AF | SH | >0 outside expected | QC | Red if >0 Quarterly ER if >0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | Non compliance with 14/15 published NICE guidance | AF | SH | 0 | QC | Red if in mth >0 ER if 2 consecutive mths Red | New Indicator for 14/15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | E15 | ROSC in Utstein Group | AF | PR | твс | TDA | TBC | | | | | | NE | EW TDA | INDICATO | OR - DEFI | | D BE CO | NFIRMED |) | | | | | |
| | E16 | STEMI 150minutes | AF | PR | TBC | TDA | TBC | | | | | | NE | EW TDA | INDICAT | OR - DEFI | | D BE CO | NFIRMED |) | | | | | |

-

| | KPI Ref Indicators | Board Director | Lead Officer | 15/16 Target | Target Set by | Red RAG/ Exception Report Threshold (ER) | 13/14 Outturn | 14/15 Outturn | Sep-14 | Oct-14 | Nov-14 | Dec-14 | Jan-15 | Feb-15 | Mar-15 | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | YTD |
|-------|---|-------------------|-----------------|------------------------|------------------|--|-------------------------------|------------------|--------|----------|-------------|--------|--------|----------|-----------|----------|-----------|---------|--------|--------|----------|--------|--------|-------|
| | R1 ED 4 Hour Waits UHL + UCC (Calendar Month) | RM | L | 95% or above | TDA | Red if <92% ER via ED TB report | 88.4% | 89.1% | 91.6% | 89.8% | 89.1% | 83.0% | 90.7% | 89.6% | 91.1% | 92.0% | 92.2% | 92.6% | 92.2% | 90.6% | 90.3% | 88.9% | 81.7% | 90.0% |
| | R2 12 hour trolley waits in A&E | RM | L | 0 | TDA | Red if >0 ER via ED TB report | 5 | 4 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| | R3 RTT - Incomplete 92% in 18 Weeks | RM | WM | 92% or above | TDA | Red /ER if <92% | 92.1% | 96.7% | 94.3% | 94.8% | 95.0% | 95.1% | 95.2% | 96.2% | 96.7% | 96.6% | 96.5% | 96.2% | 95.2% | 94.3% | 94.8% | 93.6% | 93.8% | 93.8% |
| | R4 RTT 52 Weeks+ Wait (Incompletes) | RM | WM | 0 | TDA | Red /ER if >0 | 0 | 0 | 3 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 66 | 242 | 256 | 258 | 260 | 265 | 263 | 263 |
| | R5 6 Week - Diagnostic Test Waiting Times | RM | SK | 1% or below | TDA | Red /ER if >1% | 1.9% | 0.9% | 1.0% | 0.7% | 1.8% | 2.2% | 5.0% | 0.8% | 0.9% | 0.8% | 0.6% | 6.1% | 10.9% | 13.4% | 9.6% | 7.7% | 6.5% | 6.5% |
| | R6 Urgent Operations Cancelled Twice | RM | PW | 0 | TDA | Red if >0 ER if >0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ď | R7 Cancelled patients not offered a date within 28 days of the cancellations UHL | RM | PW | 0 | TDA | Red if >2 ER if >0 | 85 | 33 | 2 | 2 | 0 | 3 | 4 | 3 | 1 | 2 | 0 | 1 | 1 | 5 | 1 | 0 | 3 | 13 |
| nsiv | R8 Cancelled patients not offered a date within 28 days of the cancellations ALLIANCE | RM | PW | 0 | TDA | Red if >2 ER if >0 | New Indicator for 14/15 | 11 | 0 | 0 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| 0 0 5 | % Operations cancelled for non-clinical reasons | RM | PW | 0.8% or below | Contract | Red if >0.9% ER if >0.8% | 1.6% | 0.9% | 0.8% | 0.8% | 1.2% | 1.1% | 0.8% | 0.7% | 1.0% | 0.7% | 0.5% | 0.9% | 1.3% | 0.7% | 0.9% | 0.8% | 1.3% | 0.9% |
| B | Source Sections Cancelled for non-clinical reasons | RM | PW | 0.8% or below | Contract | Red if >0.9% ER if >0.8% | 1.6% | 0.9% | 0.9% | 1.0% | 0.0% | 0.8% | 1.4% | 0.0% | 0.4% | 1.2% | 1.2% | 1.0% | 0.8% | | 1.0% | 1.1% | - | 0.8% |
| | R11 % Operations cancelled for non-clinical reasons on or after the day of admission UHL + ALLIANCE | RM | PW | 0.8% or below | Contract | Red if >0.9% ER if >0.8% | New Indicator for 14/15 | 0.9% | 0.8% | 0.8% | 1.1% | 1.1% | 0.8% | 0.7% | 0.9% | 0.8% | 0.6% | 0.9% | 1.3% | 0.7% | 0.9% | 0.8% | 1.2% | 0.9% |
| | No of Operations cancelled for non-clinical R12 reasons on or after the day of admission UHL + ALLIANCE | RM | PW | N/A | UHL | TBC | 1739 | 1071 | 90 | 94 | 108 | 102 | 85 | 64 | 98 | 79 | 56 | 97 | 138 | 67 | 104 | 91 | 131 | 763 |
| | R13 Outpatient Hospital Cancellation Rates | RM | PW | Within Upper Decile | UHL | TBC | | · · · | | <u> </u> | | | NEW T | DA INDIC | ATOR - DE | FINITION | TO BE COM | NFIRMED | | | | • | | |
| | R14 Delayed transfers of care | RM | PW | 3.5% or below | TDA | Red if >3.5% ER if Red for 3 consecutive mths | 4.1% | 3.9% | 4.5% | 4.6% | 5.2% | 3.9% | 3.2% | 2.9% | 1.8% | 1.2% | 1.0% | 1.0% | 0.9% | 1.2% | 1.3% | 1.1% | 1.3% | 1.1% |
| | R15 NHS e-Referral (formally Choose and Book Slot Unavailability) | RM | WM | 4% or below | Contract | Red if >4% ER if Red for 3 consecutive mths | 13% | 21% | 25% | 20% | 17% | 16% | 13% | 19% | 26% | 34% | 31% | | | Data | Not Avai | ilable | | |
| | R16 Ambulance Handover >60 Mins (CAD+ from June 15) | RM | PW | 0 | Contract | Red if >0 ER if Red for 3 consecutive mths | New Indicator for 14/15 | 5% | 2% | 5% | 6% | 10% | 6% | 11% | 9% | 6% | 7% | 7% | 8% | 9% | 18% | 22% | 27% | 13% |
| | R17 Ambulance Handover >30 Mins and <60 mins (CAD+ from June 15) | RM | PW | 0 | Contract | Red if >0 ER if Red for 3 consecutive mths | New Indicator for 14/15 | 19% | 17% | 25% | 23% | 25% | 21% | 21% | 22% | 22% | 21% | 17% | 17% | 17% | 25% | 26% | 26% | 21% |

Safe Caring Well Led Effective Responsive Research

8

| | | Caring | | | | Effective | | Responsive | | |
|--|--|--------|--|--|--|-----------|--|------------|--|--|
|--|--|--------|--|--|--|-----------|--|------------|--|--|

RC22 Rare Cancers

RC23 Grand Total

RM

RM

ММ

ММ

85% or above

85% or above

TDA

TDA

| | KPI Ref | Indicators | Board Director | Lead Officer | 15/16 Target | Target Set by | Red RAG/ Exception Report Threshold (ER) | 13/14 Outturn | 14/15 Outturn | Oct-14 | Nov-14 | Dec-14 | Jan-15 | Feb-15 | Mar-15 | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | YTD |
|------|---|---|---|---|---|--|---|--|---|--|--|---|--|--|--|---|--|--|---|--|--|--|--|---|
| | ** Cancer | statistics are reported a month in arrears. | | | | | | | | | | | | | | | | | | | | | | |
| | RC1 | Two week wait for an urgent GP referral for suspected cancer to date first seen for all suspected cancers | RM | мм | 93% or above | TDA | Red if <93% ER if Red for 2 consecutive mths | 94.8% | 92.2% | 92.0% | 92.5% | 93.0% | 92.2% | 93.5% | 91.5% | 91.2% | 87.9% | 91.1% | 87.4% | 86.8% | 88.7% | 90.0% | ** | 88.9% |
| | RC2 | Two Week Wait for Symptomatic Breast Patients (Cancer Not initially Suspected) | RM | мм | 93% or above | TDA | Red if <93% ER if Red for 2 consecutive mths | 94.0% | 94.1% | 98.6% | 100.0% | 93.0% | 92.5% | 91.5% | 96.0% | 99.0% | 98.8% | 87.2% | 93.3% | 98.7% | 94.5% | 94.6% | ** | 95.1% |
| | RC3 | 31-Day (Diagnosis To Treatment) Wait For First Treatment: All Cancers | RM | мм | 96% or above | TDA | Red if <96% ER if Red for 2 consecutive mths | 98.1% | 94.6% | 95.9% | 92.5% | 95.2% | 91.7% | 95.0% | 97.0% | 93.9% | 97.9% | 93.7% | 97.2% | 96.5% | 94.7% | 95.2% | ** | 95.6% |
| | RC4 | 31-Day Wait For Second Or Subsequent Treatment: Anti Cancer Drug Treatments | RM | мм | 98% or above | TDA | Red if <98% ER if Red for 2 consecutive mths | 100.0% | 99.4% | 97.1% | 100.0% | 96.7% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 97.7% | 100.0% | 98.3% | 100.0% | 100.0% | ** | 99.4% |
| | RC5 | 31-Day Wait For Second Or Subsequent Treatment: Surgery | RM | мм | 94% or above | TDA | Red if <94% ER if Red for 2 consecutive mths | 96.0% | 89.0% | 81.9% | 82.4% | 80.3% | 89.2% | 94.4% | 87.5% | 86.3% | 92.2% | 89.6% | 92.2% | 81.1% | 89.7% | 90.6% | ** | 88.8% |
| | RC6 | 31-Day Wait For Second Or Subsequent Treatment: Radiotherapy Treatments | RM | мм | 94% or above | TDA | Red if <94% ER if Red for 2 consecutive mths | 98.2% | 96.1% | 96.0% | 94.7% | 95.5% | 87.6% | 99.0% | 100.0% | 86.3% | 98.1% | 96.5% | 95.9% | 99.0% | 92.2% | 94.0% | ** | 94.8% |
| | RC7 | 62-Day (Urgent GP Referral To Treatment) Wait For First Treatment: All Cancers | RM | мм | 85% or above | TDA | Red if <85% ER if Red in mth or YTD | 86.7% | 81.4% | 80.4% | 77.0% | 84.8% | 79.3% | 78.9% | 83.8% | 75.7% | 70.1% | 84.2% | 73.7% | 81.7% | 77.2% | 77.0% | ** | 77.2% |
| er | RC8 | 62-Day Wait For First Treatment From Consultant Screening Service Referral: All Cancers | RM | мм | 90% or above | TDA | Red if <90% ER if Red for 2 consecutive mths | 95.6% | 84.5% | 75.0% | 94.4% | 93.8% | 88.9% | 79.4% | 89.3% | 91.7% | 82.4% | 93.3% | 95.2% | 97.1% | 81.4% | 96.2% | ** | 91.1% |
| ance | RC9 | Cancer waiting 104 days | RM | мм | 0 | TDA | TBC | | | NE | EW TDA IN | DICATOR | | • | | 12 | 10 | 12 | 20 | 12 | 12 | 17 | 13 | 13 |
| C | | | | | | | | | | | | | | | | | | | | | | | | |
| sive | 62-Dav | | | | | | | | | | | | | | | | | | | | | | | |
| on | | (Urgent GP Referral To Treatment) Wait For Firs | st Treatm | ent: All (| Cancers Inc Bar | e Cancers | | | | | | | | | | | | | | | | | | |
| | | (Urgent GP Referral To Treatment) Wait For Firs | Board Director | Lead Officer | Cancers Inc Rar | Target Set | Red RAG/ Exception Report Threshold (ER) | 13/14 Outturn | 14/15 Outturn | Oct-14 | Nov-14 | Dec-14 | Jan-15 | Feb-15 | Mar-15 | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | YTD |
| ds | KPI Ref | | Board | Lead | 1 | Target Set | Threshold (ER) Red if <90% | | | Oct-14 | Nov-14 | Dec-14 | Jan-15 | Feb-15 | Mar-15 | Apr-15 | May-15 100.0% | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | Nov-15 | үт <u>р</u> 100.0% |
| | KPI Ref | Indicators | Board Director | Lead Officer | 15/16 Target | Target Set by | Threshold (ER) | Outturn | Outturn | | Nov-14 81.8% | Dec-14 100.0% | | Feb-15 97.4% | | Apr-15 92.3% | - | Jun-15 97.8% | | Aug-15 96.3% | | Oct-15 92.0% | | |
| es | KPI Ref RC10 RC11 | Indicators Brain/Central Nervous System | Board Director | Lead Officer MM | 15/16 Target 85% or above | Target Set by TDA | Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90% | Outturn 100.0% | Outturn | | | | 93.3% | | | | 100.0% | | | 96.3% | | | ** | 100.0% |
| es | KPI Ref RC10 RC11 RC12 | Indicators Brain/Central Nervous System Breast | Board Director RM RM | Lead Officer MM MM | 15/16 Target 85% or above 85% or above | Target Set by TDA TDA | Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90% ER if Red for 2 consecutive mths Red if <90% ER if Red for 2 consecutive mths Red if <90% ER if Red for 2 consecutive mths | Outturn 100.0% 96.1% | Outturn 92.6% | 96.3% | 81.8% | 100.0% | 93.3% 54.5% | 97.4% | 98.1% | 92.3% | 100.0% 96.8% | 97.8% | 91.4% | 96.3% | 97.5% | 92.0% | ** | 100.0% 95.0% |
| es | KPI Ref RC10 RC11 RC12 RC13 | Indicators Brain/Central Nervous System Breast Gynaecological | Board Director RM RM RM | Lead Officer MM MM MM | 15/16 Target 85% or above 85% or above 85% or above | Target Set by TDA TDA TDA TDA | Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90% ER if Red for 2 consecutive mths Red if <90% ER if Red for 2 consecutive mths Red if <90% Red if <90% | Outturn 100.0% 96.1% 88.2% | Outturn 92.6% 77.5% | 96.3% 71.4% | 81.8% 75.0% | 100.0% 66.7% | 93.3% 54.5% | 97.4% 91.7% | 98.1% 75.0% | 92.3% 64.3% | 100.0% 96.8% 55.6% | 97.8% 66.7% | 91.4% 100.0% | 96.3% 72.2% | 97.5% 80.0% | 92.0% 84.6% | ** | 100.0% 95.0% 74.1% |
| es | KPI Ref RC10 RC11 RC12 RC13 RC14 | Indicators Brain/Central Nervous System Breast Gynaecological Haematological | Board Director RM RM RM RM | Lead Officer MM MM MM MM | 15/16 Target85% or above85% or above85% or above85% or above | Target Set by TDA TDA TDA TDA TDA | Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90% ER if Red for 2 consecutive mths | Outturn 100.0% 96.1% 88.2% 65.9% | Outturn 92.6% 77.5% 66.5% | 96.3% 71.4% 100.0% | 81.8% 75.0% 73.3% | 100.0% 66.7% 75.0% | 93.3% 54.5% 66.7% | 97.4% 91.7% 50.0% | 98.1% 75.0% 80.0% | 92.3% 64.3% 50.0% | 100.0% 96.8% 55.6% 55.0% | 97.8% 66.7% 83.3% | 91.4% 100.0% 37.5% | 96.3% 72.2% 82.6% | 97.5% 80.0% 66.7% | 92.0% 84.6% 70.0% | ** ** ** ** | 100.0% 95.0% 74.1% 63.5% |
| es | KPI Ref RC10 RC11 RC12 RC13 RC14 | Indicators Brain/Central Nervous System Breast Gynaecological Haematological Head and Neck Lower Gastrointestinal Cancer | Board Director RM RM RM RM | Lead Officer MM MM MM MM | 15/16 Target 85% or above | Target Set by TDA TDA TDA TDA TDA TDA | Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90% | Outturn 100.0% 96.1% 88.2% 65.9% 65.4% | Outturn 92.6% 77.5% 66.5% 69.9% | 96.3% 71.4% 100.0% 100.0% | 81.8% 75.0% 73.3% 33.3% | 100.0% 66.7% 75.0% 77.8% | 93.3% 54.5% 66.7% 70.0% | 97.4% 91.7% 50.0% 87.5% | 98.1% 75.0% 80.0% 62.5% | 92.3% 64.3% 50.0% 75.0% | 100.0% 96.8% 55.6% 55.0% 54.5% | 97.8% 66.7% 83.3% 66.7% | 91.4% 100.0% 37.5% 36.4% | 96.3% 72.2% 82.6% 60.9% | 97.5% 80.0% 66.7% 50.0% | 92.0% 84.6% 70.0% 75.0% | ** ** ** ** | 100.0% 95.0% 74.1% 63.5% 56.7% |
| es | KPI Ref RC10 RC11 RC12 RC13 RC14 RC15 | Indicators Brain/Central Nervous System Breast Gynaecological Haematological Head and Neck Lower Gastrointestinal Cancer Lung | Board Director RM RM RM RM RM RM | Lead Officer MM MM MM MM MM | 15/16 Target 85% or above | Target Set by TDA TDA TDA TDA TDA TDA TDA | Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90% ER if Red for 2 consecutive mths | Outturn 100.0% 96.1% 88.2% 65.9% 65.4% 71.3% | Outturn 92.6% 77.5% 66.5% 69.9% 63.7% | 96.3% 71.4% 100.0% 100.0% 56.3% 68.9% | 81.8% 75.0% 73.3% 33.3% 62.5% | 100.0% 66.7% 75.0% 77.8% 92.9% 74.4% | 93.3% 54.5% 66.7% 70.0% 65.0% 67.7% | 97.4% 91.7% 50.0% 87.5% 46.7% 74.2% | 98.1% 75.0% 80.0% 62.5% 63.2% 88.6% | 92.3% 64.3% 50.0% 75.0% 63.6% | 100.0% 96.8% 55.6% 55.0% 54.5% 55.6% | 97.8% 66.7% 83.3% 66.7% 93.3% | 91.4% 100.0% 37.5% 36.4% 63.6% | 96.3% 72.2% 82.6% 60.9% 60.0% | 97.5% 80.0% 66.7% 50.0% 38.9% | 92.0% 84.6% 70.0% 75.0% | ** ** ** ** ** | 100.0% 95.0% 74.1% 63.5% 56.7% 62.9% |
| es | KPI Ref RC10 RC11 RC12 RC13 RC14 RC15 RC16 RC17 | Indicators Brain/Central Nervous System Breast Gynaecological Haematological Head and Neck Lower Gastrointestinal Cancer Lung | Board Director RM RM RM RM RM RM | Lead Officer MM MM MM MM MM MM | 15/16 Target 85% or above | Target Set by TDA TDA TDA TDA TDA TDA TDA | Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90% | Outturn 100.0% 96.1% 88.2% 65.9% 65.4% 71.3% 89.7% | Outturn 92.6% 77.5% 66.5% 69.9% 63.7% 69.9% | 96.3% 71.4% 100.0% 100.0% 56.3% 68.9% | | 100.0% 66.7% 75.0% 77.8% 92.9% 74.4% | 93.3% 54.5% 66.7% 70.0% 65.0% 67.7% | 97.4% 91.7% 50.0% 87.5% 46.7% 74.2% | 98.1% 75.0% 80.0% 62.5% 63.2% 88.6% | 92.3% 64.3% 50.0% 75.0% 63.6% 84.6% | 100.0% 96.8% 55.6% 55.0% 54.5% 55.6% | 97.8% 66.7% 83.3% 66.7% 93.3% 74.6% | 91.4% 100.0% 37.5% 36.4% 63.6% 81.8% | 96.3% 72.2% 82.6% 60.9% 60.0% | 97.5% 80.0% 66.7% 50.0% 38.9% 73.5% | 92.0% 84.6% 70.0% 75.0% 65.2% | ** ** ** ** ** ** | 100.0% 95.0% 74.1% 63.5% 56.7% 62.9% 70.4% |
| es | KPI Ref RC10 RC11 RC12 RC13 RC14 RC15 RC16 RC17 | Indicators Brain/Central Nervous System Breast Gynaecological Haematological Head and Neck Lower Gastrointestinal Cancer Lung Other Sarcoma | Board Director RM RM RM RM RM RM RM | Lead Officer MM MM MM MM MM MM | 15/16 Target 85% or above | Target Set by TDA TDA TDA TDA TDA TDA TDA | Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90% ER if Red for 2 consecutive mths | Outturn 100.0% 96.1% 88.2% 65.9% 65.4% 71.3% 89.7% 78.7% | Outturn 92.6% 77.5% 66.5% 69.9% 63.7% 69.9% 95.0% | 96.3% 71.4% 100.0% 56.3% 68.9% 100.0% | 81.8% 75.0% 73.3% 33.3% 62.5% 64.1% 100.0% | 100.0% 66.7% 75.0% 77.8% 92.9% 74.4% 100.0% | 93.3% 93.3% 66.7% 70.0% 65.0% 67.7% | 97.4% 91.7% 50.0% 87.5% 46.7% 74.2% 100.0% | 98.1% 95.0% 80.0% 62.5% 63.2% 88.6% 100.0% | 92.3% 64.3% 50.0% 63.6% 84.6% 50.0% | 100.0% 96.8% 55.6% 55.0% 54.5% 55.6% 50.9% 100% | 97.8% 966.7% 83.3% 66.7% 93.3% 74.6% | 91.4% 100.0% 37.5% 36.4% 63.6% 81.8% 100% | 96.3% 72.2% 82.6% 60.9% 60.0% | 97.5% 80.0% 66.7% 50.0% 38.9% 73.5% 50.0% | 92.0% 84.6% 70.0% 75.0% 65.2% 60.0% | ** ** ** ** ** ** | 100.0% 95.0% 74.1% 63.5% 56.7% 62.9% 70.4% |
| es | KPI Ref RC10 RC11 RC12 RC13 RC14 RC15 RC16 RC16 RC17 RC18 RC19 | Indicators Brain/Central Nervous System Breast Gynaecological Haematological Head and Neck Lower Gastrointestinal Cancer Lung Other Sarcoma | Board Director RM RM RM RM RM RM RM RM | Lead Officer MM MM MM MM MM MM MM | 15/16 Target 85% or above 85% or above | Target Set by TDA TDA TDA TDA TDA TDA TDA TDA | Threshold (ER) Red if <90% ER if Red for 2 consecutive mths Red if <90% | Outturn 100.0% 96.1% 88.2% 65.9% 65.4% 71.3% 89.7% 78.7% 82.9% | Outturn 92.6% 77.5% 66.5% 69.9% 63.7% 69.9% 95.0% 46.2% | 96.3% 71.4% 100.0% 56.3% 68.9% 100.0% | | 100.0% 66.7% 75.0% 77.8% 92.9% 74.4% 100.0% | 93.3% 54.5% 66.7% 70.0% 65.0% 67.7% 100.0% | 97.4% 91.7% 50.0% 87.5% 46.7% 74.2% 100.0% | 98.1% 75.0% 80.0% 63.2% 88.6% 100.0% | 92.3% 64.3% 50.0% 63.6% 84.6% 50.0% 66.7% | 100.0% 96.8% 55.6% 55.0% 55.6% 50.9% 100% | 97.8% 66.7% 83.3% 66.7% 93.3% 74.6% 100% | 91.4% 100.0% 37.5% 36.4% 63.6% 81.8% 100% | 96.3% 72.2% 82.6% 60.9% 60.0% 70.4% 100% | 97.5% 80.0% 66.7% 50.0% 38.9% 73.5% 50.0% 80.0% | 92.0% 84.6% 70.0% 75.0% 65.2% 60.0% | ** ** ** ** ** ** ** | 100.0% 95.0% 74.1% 63.5% 62.9% 70.4% 70.4% 75.0% |

92.3% 84.6%

86.7% 81.4%

100.0% 100.0% 100.0% 100.0% 66.7% 100.0%

80.4% 77.0% 84.8% 79.3% 78.9% 83.7%

100% 100% 100% 100.0% 100.0% 100.0%

75.7% 70.1% 84.2% 73.7% 81.7% 77.2% 77.0%

**

**

100%

77.2%

Red if <90% ER if Red for 2 consecutive mths

Red if <90%

ER if Red for 2 consecutive mths

Compliance Forecast for Key Responsive Indicators

| Standard | November actual/predicted | December predicted | Month by which to be compliant | RAG rating of required month delivery | Commentary |
|--|------------------------------|-----------------------|-----------------------------------|--|--|
| Emergency Care | | | 1 | | |
| 4+ hr Wait (95%) - Calendar month | 81.7% | | March, 2016 | | |
| Ambulance Handover (CAD+) | | | - - | | |
| % Ambulance Handover >60 Mins (CAD+) | 27% | | Not Confirmed | | An eight-week action plan has been agreed to speed up the time it takes for EMAS crews to pass patients to A&E staff at Leicester Royal Infirmary. November data |
| % Ambulance Handover >30 Mins and <60 mins (CAD+) | 26% | | Not Confirmed | | expected this week. |
| RTT (inc Alliance) | | | | | |
| Incomplete (92%) | 93.8% | 93.5% | | | |
| Diagnostic (predicted) DM01 - diagnostics 6+ week waits (<1%) # Neck of femurs | 6.5% | | February, 2016 | | NHS IQ Work progressing. |
| % operated on within 36hrs - admissions (72%) | 72.0% | 72.0% | | | August and September delivered for the first time in over a year. |
| Cancelled Ops (inc Alliance) | | | | | |
| Cancelled Ops (0.8%) | 1.2% | 0.8% | December | | November target missed due to increased emergency pressures. |
| Not Rebooked within 28 days (0 patients) | 3 | 4 | January, 2016 | | December at risk - to be validated. |
| Cancer (predicted) | | | | | |
| Two Week Wait (93%) | 93% | 93% | November | | At risk for November. |
| 31 Day First Treatment (96%) | 92% | 85% | February, 2016 | | Delivery rephased. |
| 31 Day Subsequent Surgery Treatment (94%) | 88% | 90% | January, 2016 | | Delivery rephased. |
| 62 Days (85%) | 78% | 80% | June, 2016 | | The rephasing of delivery has been revised to June 2016, given the challenge we and other centres are experiencing and the backlog not being where we need it to be. Nationally this target hasn't been achieved since April 2014. |
| Cancer waiting 104 days (0 patients) | 13 | 13 | | | |



| | KPI Ref | Indicators | Board Director | Lead Officer | 14/15 Target | Target Set by | Red RAG/ Exception Report Threshold (ER) | Apr-14 | May-14 | Jun-14 | Jul-14 | Aug-14 | Sep-14 | Oct-14 | Nov-14 | Dec-14 | Jan-15 | Feb-15 | Mar-15 | YTD | Apr-15 | May-15 | Jun-15 | Jul-15 | Aug-15 | Sep-15 | Oct-15 | YTD |
|----------|---------|---|-------------------|-----------------|--|------------------|---|--------|---------------------------------------|--------|--------|--------------------|--------|--------|---------------------|--------|--------|---------|----------------|--------|---------|---------|--------|--------|---------------------|---------------|--------|---------|
| | RU1 | Median Days from submission to Trust approval (Portfolio) | AF | NB | TBC | TBC | TBC | | 3.0 | | | 2.0 | | | 3.0 | | | 3.0 | | 2.8 | | 2.0 | | | 1.0 | | | 2.0 |
| IHI | RU2 | Median Days from submission to Trust approval (Non Portfolio) | AF | NB | TBC | TBC | TBC | | 2.0 | | | 3.5 | | | 2.0 | | | 1.0 | | 2.1 | | 4.0 | | | 1.0 | | | 4.0 |
| d or c h | RU3 | Recruitment to Portfolio Studies | AF | NB | Aspirational target=10920/year (910/month) | TBC | TBC | 941 | 1092 | 963 | 1075 | 1235 | 900 | 1039 | 1048 | 604 | 1030 | 1043 | 1298 | 12564 | 1078 | 869 | 1165 | 999 | 862 | 979 | 1255 | 7207 |
| Doco | RIN | % Adjusted Trials Meeting 70 day Benchmark (data sunbmitted for the previous 12 month period) | AF | NB | TBC | TBC | TBC | (Ju | 13-Jun 43.4% | 14) | (Oc | t13-Sep 70.5% | • | (No | v13-De 70.5% | • | (A) | pr14-Ma | ar15) 86 | 5% | (Jul1 | 4-Jun15 |) 76% | | Report availab | not yet le | | 76% |
| | 1 8115 | Rank No. Trials Submitted for 70 day Benchmark (data submitted for the previous 12 month period) | AF | NB | TBC | TBC | TBC | • | 43.4% (Jul13-Jun14) Rank 17/61 | | • | t13-Sep ank 18/ | • | | ov13-De lank 18/ | • | (Apr14 | l-Mar15 |) Rank (| 60/198 | ul14-Ju | ın15) | 108/2 | | l Report availab | not yet le | | 108/210 |
| | | %Closed Commercial Trials Meeting Recruitment Target (data submitted for the previous 12 month period) | AF | NB | TBC | TBC | TBC | (Ju | | | (Oc | t13-Sep 52% | o14) | (No | ov13-De 48% | c14) | (Ap | r14-Mai | '15) 38 | .6% | (Jul14 | -Jun15) | 15.3% | | Report availab | not yet le | | 15.3% |

| What is causing underperformance? | What actions have been taken to improve performance? | Target (mthly / end of year) | nthly / October nd of performance | | nce YTD performance | | ce Forecast performance reporting period | | | |
|--|---|---------------------------------------|--------------------------------------|------------------|--------------------------------------|------------|--|---------------|--------|------------------|
| UHL's readmission rate | A 'Readmissions Review' CQUIN was | Within Expected | 9.0% | | 9.0% | | | | 9.0% | |
| 15/16 and when compared with other | the Review has now been complete. This highlighted a need for: | | | RAT | E 12/13 to 14/1 | 5 (as meas | sured | | | _ |
| Foster tool) our 'risk | readmission, in order to inform discharge | F/Y | Super Sp | ells | Observed | Rate (%) | | Relat Risk | live | |
| | | 2012/13 | 220 | 024 | 17414 | | 7.91 | | 103.1 | 5 |
| Ű, | | | | | 17294 | | 7.85 | | 102.4 | |
| past 3 years. | been agreed to proceed with the PARR30 | | | | 20418 | | 8.42 | | 106.3 | |
| | tool as this can be automated from data available in the Trust's data warehouse. | - | | | | I. | | н отн | | |
| | | TRUST | | | | Discharges | s Ba | eAdm | % | RELATIVE RISK |
| | Response Services to confirm what support | | ospitals Bristo | NHS | Eoundation Trust | | | 8446 | 6.46 | 88.51 |
| | can be provided for patients identified as | | | | | 19179 | | 4650 | 7.64 | 95.14 |
| | 0 | | | | | 17804 | | 2541 | 7.04 | 97.02 |
| | | | | | · · · | 14719 | 0 1 | 1849 | 8.05 | 98.92 |
| | | South Tees | Hospitals NHS | S Four | ndation Trust | 15342 | 7 1 | 2636 | 8.24 | 100.65 |
| | | Oxford Unive | ersity Hospital | ls NHS | S Trust | 19837 | 2 14 | 4779 | 7.45 | 102.77 |
| | | Nottingham | University Ho | spitals | NHS Trust | 20461 | 9 18 | 8603 | 9.09 | 103.06 |
| | sharing care planning between LLR | | | <u> </u> | | | | 0330 | 9.55 | 105.23 |
| | organisations. | | | | | 24226 | | 0375 | 8.41 | 106.4 |
| | | | | | | 17678 | | 6220 | 9.18 | 106.77 |
| | What actions have been taken to improve performance?(mthly / end of year)October performanceA 'Readmissions Review' CQUIN was agreed with Commissioners for 15/16 and the Review has now been complete. This highlighted a need for: Better identification of patients at risk of readmission, in order to inform discharge planning and community follow up and support. Following review of the different Readmission Risk tools available, it has been agreed to proceed with the PARB30 tool as this can be automated from data available in the Trust's data warehouse. Discussions are taking place with the City and County Integrated Community Response Services to confirm what support this discussion. Joint care planning for patients with Long Term Conditions and End of Life Care Needs. Actions being taken are to investigate the most effective IT solution for sharing care planning between LLR | | | 22104 | | 8764 | 8.49 | 111.66 | | |
| What is causing underperformance?What actions have been taken to improve performance?(mthly / end of year)JHL's readmission rate has increased during 15/16 and when compared with other Trusts (using the Dr Foster tool) our 'risk adjusted readmission, in order to inform discharge planning and community follow up and support. Following review of the different Readmission, Risk tools available, it has been agreed to proceed with the PARR30 tool as this can be automated from data available in the Trust's data warehouse. Discussions are taking place with the City and County Integrated Community Response Services to confirm what support can be provided for patients identified as being at risk. Further data needed to inform this discussion. Joint care planning for patients with Long Term Conditions and End of Life Care Needs. Actions being taken are to investigate the most effective IT solution for sharing care planning between LLR organisations. Long term catheter service in the community. At a meeting with LPT nursing services, a project plan has been agreed to investigate the most effective IT solution for sharing care planning between LLR organisations. Long term catheter service in the community. At a meeting with LPT nursing services, a project plan has been agreed to investigate the most effective IT solution for shering care planning between LLR organisations. Long term catheter service in the community. At a meeting with LPT nursing services, a project plan has been agreed to reduce their rates – eg 'Hot Gall Bladder Service' in General Surgery andExpecter term tere to target Lead Diri | University He | ospital Southa | amptor | n NHS Foundation | 13431 | 9 12 | 2991 | 9.67 | 112.74 | |
| | | | | | | | | | | |
| | | Expected d | late to | | | | | | | |
| | | | lard / | TBC - | - following imple | mentation | of acti | ions. | | |
| | Service' in General Surgery and | Lead Direct | | | ew Furlong, Inter Jameson, Interi | ctor | | | | |

| What is causing underperformance? | What actions have been taken to improve performance? | Target (mthly / end of year) | November performance | YTD performance | Forecast performance for next reporting period |
|---|---|--|--|---|---|
| The Trust had 263 patients on an incomplete pathway that breached 52 | The service is now closed to new referrals with some clinical exceptions. | 0 | 263 | 263 | c. 260 |
| weeks at the end of October 2015. All patients were from the Orthodontics Department. The reasons for underperformance in Orthodontics are as follows: Incorrect use and management of a planned waiting list for outpatients. Inadequate capacity within the service to see patients when they are ready for treatment. There are currently 10 patients on the waiting list between 40 and 51 weeks, who are likely to roll over to become 52 week breaches. | Adherence to this is being monitored by the Director of Performance and Information. Funding has been secured from NHS England for 2 WTE locums to clear the backlog. So far, recruitment attempts have been unsuccessful. The Serious Untoward Incident (SUI) report was recently published. Recommendations included a clearly defined SOP to be put in place for the administration of planned waiting lists and that all administrative and clinical staff running outpatient clinics should have RTT e-learning training. UHL are exploring capacity for Orthodontics patients within both community and acute providers in the local area. Around 24 patients will transfer to Northampton General Hospital, approximately 20 are expected to be treated at Oakham Dental Studio and 77 patients will go to Clearly Orthodontics once contracts have been signed. Additional capacity is being | deliberate, Tru Therefore the f Community relevant si System re All Generaty confirming returned to Weekly re Performany identify and | st-wide review of following actions h cation around pla taff; eview of all waiting al Managers and g review and as o Richard Mitchell view at Heads of nce team to revi eas of risk. | planned waiting li nave been taken T anned waiting list list codes; Heads of Service ssurance of all ; Ops meeting for a | management to all have signed a letter waiting lists, to be |
| | explored with Hallcross Dental, Manor House, United LincoInshire Hospitals NHS Trust and Ramsay Healthcare | meet standard target Lead Director Lead Officer | / Richard I | | erating Officer Ferformance and |

| What is causing underperformance? | What actions have been taken to improve performance? | Target (mthly / end of year) | | | nce) | ce Y F | /TD performa UHL Alli | | Forecas perform for next | nance | |
|-------------------------------------|--|---|-----------------|--|---|---------------|---------------------------------|--------------------|--------------------------------|-----------|-------|
| Imaging Although final validated | Imaging Machine stability remains an issue; all extra capacity | | <1% | (pi | 6.5% redicted | | | dicted) | Т | вс | _ |
| | is being utilised in MRI to minimise the number of breaches. An MRI van will be on site for two weeks in January and we are currently exploring the feasibility of extending outpatient MRI times to beyond the current end of 8pm. Approximately 100 MRIs are being sent to Nuffield each month. Endoscopy The Trust is working with a number of IS providers to obtain extra capacity, including Medinet, Circle, Your World Doctors and Nuffield. Your World Doctors are also backfilling lists during the week, which would otherwise be cancelled. The Trust will also be part of an initiative led by the Tripartite around securing extra capacity within the Independent Sector and other NHS Trusts for Endoscopy, UHL has submitted its requirements for this process but so far has obtained no extra capacity via this route. The extra capacity is complemented by a robust action plan aimed at addressing general performance issues in Gastroenterology, with particular focus on | brea The | aches pe | Apr-15 Imaging ng gra er montl pelow o | May-15 g (incl DEX aph ou h for 15 outlines | Jun-15 (A) | Jul-15 Endoscopy the tota | Aug-15 Si Other | cp-15 Oct I otal | iagnostic | |
| | ensuring that all lists are fully booked and efforts to | | | Apr | Мау | Jun | Jul | Aug | Sep | Oct | YTD |
| | improve Cancer performance via access to | | UHL | 0.9% | 0.6% | 6.97% | 12.40% | 14.92% | 10.82% | 8.85% | 8.85% |
| | Endoscopy tests. There has also been a management review in the department and an Endoscopy Manager | | UHL Alliance | 0.8% | 0.5% | 6.16% | 10.92% | 13.37% | 9.60% | 7.75% | 9.60% |
| | has been appointed to focus solely on the service, in post since early September. The Trust invited the IST to assist with capacity analysis, this has confirmed the shortfall that exists. In addition NHSIQ have been working in the endoscopy units alongside our teams on process improvements. | NB: The graph and table above have not been updated for | | | | | | | | | |
| | | Offi | | | | | ne Khalid | | | | |

Cancelled patients not offered a date within 28 days of the cancellations

INDICATORS: The cancelled operations target comprises of three components: 1. The % of cancelled operations for non-clinical reasons On The Day (OTD) of admission **2**. The number of patients cancelled who are offered another date within 28 days of the cancellation

| What is causing underperformance? | What actions have been taken to improve performance? | Target (monthly) | Latest month performance | YTD performance (inc Alliance) | Forecast performance for next reporting period |
|--|--|--|---|---|--|
| Unavailability (11) Patient delayed to admission of a higher priority patient(11) Theatre and Anaesthetic staff unavailability (11). During this month 60 operations were cancelled due to capacity pressures in UHL. This is a significantly higher number of OTD cancellation compared to last month. 34 out of 38 cancellations due to ward bed unavailability were | A ongoing review of staffing for ITU is taking place to ensure that best use of staff to maintain beds in all three ITUs. Theatre managers have increased theatre capacity for the increased cancer demand by making additional lists available to reduce 28 breaches. The | 2.5% 2.0% 1.5% 1.0% 0.9% 0.5% | 1) 1.2% (1.3% UHL & 0.0% Alliance) 2) 3 (Gen Sur Paediatric Su and Paediatri ENT D Cancellations Percentages due to 2.3% 1.9% 1.8% 1.8% 1.8% 1.8% 1.65 1.4% | UHL & 0.8% Alliance) , 2) 14 Hospital Reasons from 2013 -2.0% 2.0% 6 -0.7% 0.7% | 2) 6 |
| staff shortages and increase in | ITAPS and CHUGGS Senior Managers are working together to improve theatre capacity in the long term. | | to meet standard / Or | n the day – December day – January 2016 | 2015 |
| | | Lead Director / | | chard Mitchell, Chief (il Walmsley. Head of | |

| What is causing underperformance? | What actions have been taken to improve performance? | Target (mthly / end of year) | Latest month performance | YTD performance | Forecast performance for next reporting period | | |
|---|---|--|--|---|---|--|--|
| The Trust is measured on the % of Appointment Slot Unavailability (ASI) per month. | Action plan An action plan has been written outlining steps for recovering performance. This | <4% | Unable to report | Unable to report | No forecast as unable to measure | | |
| UHL has not met the required standard of <4% for approximately two years. When it has been able to reach this standard, it has not been sustainable. The two most significant factors causing underperformance are: Shortage of outpatient capacity; Inadequate training and education of administrative staff in the set up and use of the NHS e-Referral System (ERS). The specialties with the highest number of ASIs are: General Surgery; Orthopaedics; ENT; Gynaecology. Transition to ERS: Choose and Book migrated to the new e-Referral System on Monday 15th June; The challenges experienced in the period after the cut-over have calmed down considerably with installation of Google chrome improving the speed of the system. | steps for recovering performance. This has been shared with commissioners. Capacity Additional capacity in key specialties is part of RTT recovery and sustainability plans. Training and Education Training and Education of staff in key specialties continues, to ensure that the system is adequately set up and administrative processes are fit for purpose; Meetings are taking place with the specialties experiencing the highest rate of ASIs, focusing on awareness raising and seeking named accountability. Current focus is on working with specialties with no known capacity problems, but high ASI rates to raise awareness and promote accountability. Additional resource to support the e-Referral System An ERS administrator has been in post since May; She will be working with key specialties to help reduce their ASIs and promote administrative housekeeping. | from Choose a releasing week these reports from the week means that th progress in the New Appointm In light of the ASIs on ERS, following a pilo processes rela Advice and G The Advice ar clinical advice hospital. Analy 84% of these of number to she specialties ind Respiratory M available, a loc Expected date f meet standard t target | nd Book, the HSCI kly ASI data until fu has not been con c ending 7 th June the Trust is currer to usual manner. Inent Slot Issue (A difficulties experie a new process is b ot. This process ain ted to ERS as well uidance (A&G) nd Guidance service from a a servicer visis of the last year cases, a referral into to the scale of t cluding Orthopaed fedicine to expan- teal tariff has been a March 2016 Richard Mitche | C have indicated in the notice. A data firmed. The lates and therefore is not therefore is not unable to trans SI) Process enced by services being rolled out action as promote stand ce within ERS all ather than direct ar's A&G requests o UHL is then avo this)The ERS tea dics, Rheumatolo his)The ERS tea dics, Rheumatolo and the number igreed for this | st data available is sout of date. This ack and report on s in managing their cross all specialties, UHL administrative lardised practice. lows a GP to seek ly referring into the s has found that in ided.(can we give a am is working with ogy, Urology and of A&G services | | |
| | | Lead Officer | ector / Richard Mitchell, Chief Operating Officer | | | | |

| | | Target | | | Nov 1 | 15 | | YTD | | Fore | cast | | | |
|--|---|--|--------------|----------------|-------|--------------------|--------------|-------------------------------------|---------|--------|----------------------|--|--|--------------------------|
| What is causing underperformance? | What actions have been taken to improve performance? | 0 delays over 15 minutes | | | | | | >60 min - 27% 30-60 min – 26% | | | 60 min – 30-60 min – | | | min - % min – % |
| Difficulties continue in | An eight-week action plan has been agreed to | Performance: | | I 1 1 1 | | | | | | | 1/70 | | | |
| accessing beds and high occupancy in ED leading to congestion in the | speed up the time it takes for EMAS crews to pass patients to A&E staff at Leicester Royal Infirmary. It was drawn up following a meeting | Ambulance Handover >60 Mins (CAD+ from June 15) | Apr-15 6% | May-15 7% | 7% | 301-15 8% | Aug-15 9% | 18% | 22% | | | | | |
| assessment area and delays ambulance handover. | between managers from EMAS, UHL, the TDA and CCG's. Additional actions taken include:- | Ambulance Handover >30 Mins and <60 mins (CAD+ from June 15) | 22% | 21% | 17% | 17% | 17% | 25% | 26% | 26% | 21% | | | |
| | embedding assessment bay process with help of Unipart. Ambulance crews to assess patients for streaming at point of arrival eg ambulatory streaming - lakeside or assessment bay Bed bureau patients direct to ward if beds available. Dynamic priority score in 15 mins to assess those of a high clinical need to be seen ASAP carried out by by UHL and EMAS. | Expected date to meet star Revised date to meet star Lead Director | | | T | BC BC icharc | d Mitch | nell, Cł | nief Op | perati | ng | | | |

| What is causing underperformance? | What actions have been taken to improve performance? | Target (mthly / end of year) | Latest month performance October | Performance to date 2015/16 | Forecast performance for November |
|---|---|---|--|--|--|
| 2 Week Wait 2WW performance remains under | Current Cancer performance is an area of significant concern across UHL and is being given the highest priority by the | 2WW (Target: 93%) | 90% | 88.9% | 93% |
| target. The key reason for underperformance is Endoscopy, | executive and operational teams. Since September, there have been weekly meetings chaired by the Chief Operating Officer, attended by the CMG Heads of Ops, where they are required to | 31 day 1 st (Target: 96%) | 95.2% | 95.6% | 92% |
| which has significant impact on both Lower and Upper GI 2WW performance. However Head and | account for their tumour site performance. 2 Week Wait The CT Colon pathway for Lower and Upper GI Cancer patients | 31 day sub – Surgery (Target: 94%) | 90.6% | 88.8% | 88% |
| Neck performance was also very poor due to inadequate clinical | began in November and the impact of this will be seen in the next reporting period. Head and Neck are planning to appoint a fellow, which would create 40 more 2WW slots a week. More broadly, the | 62 day RTT (Target: 85%) | 77% | 77.2% | 78% |
| capacity across the whole service. | Trust is working with CCGs to improve the quality of 2WW referrals, specifically in relation to correct process, use of appropriate clinical criteria, and preparation of patients for the | 62 day screening (Target: 90%) | 96.2% | 91.1% | 90% |
| 31 day subsequent (surgery) 31 day subsequent (surgery) was failed predominantly as a result of Urology performance. The main factor is inadequate elective capacity. 62 day RTT 62 day performance remains below target and has not been achieved nationally since April 2014. Lower/Upper GI, Lung, Head and Neck, Gynae and Urology remain the most pressured tumour sites. The main pressures on achievement are performance challenges in Endoscopy, inadequate theatre capacity and shortages in consultant staff. | urgency of appointments. 31 day subsequent (surgery) All Cancer patients coming into theatre should be escalated to the General Manager for Theatres to ensure that they are appropriately prioritised. The Cancer action plan aims to address the step-down of patients from Intensive Care, in order to pull Cancer patients through the system more quickly. It also includes significant investment in clinical staff, including a nurse specialist in Urology and consultants in Head and Neck and Dermatology. This additional capacity will help performance; yet while recruitment processes are underway, successful recruitment has been problematic due to a shortage of appropriate candidates. 62 day RTT Efforts to improve 31 day and 2WW performance will help to improve the 62 day position. The appointment of three band 7 service managers with responsibility for managing cancer pathways in our worst performing tumour sites will provide the key focus required; all are now in post. Commissioners requested a Remedial Action Plan via the formal contracting process (October 2015) to support improvement of the 62 day standard; this has been submitted and is monitored through the joint Cancer and | 120.0% 100.0% 80.0% 60.0% 40.0% 20.0% 0.0% Apr-15 2WW | May-15 Jun-15 V ay sub surgery to 2WW: Nov 31 day pa 31 day sub | Jul-15 Aug-15 S Jul-15 Aug-15 A | Sep-15 Oct-15 t treatment 2016 huary 2016 |
| | RTT board. During December there is additional focus on cancer, with the COO and Heads of Ops present at the weekly Cancer action board in order to unblock issues that prevent patient flow and treatment. A cancer LIA event in late November was well attended (90+ delegates) from both primary and secondary care, outputs from this will be part of the recovery action plan. | Revised date t meet standard Lead Director Lead Officer | No Richard M | litchell, Chief Op alfe, Clinical Lea | erating Officer |

| What is causing underperformance?What actions have been taken to improve performance? | | | | Month by month breakdown of patients breaching 104 days | | | | | | | | | |
|--|---|---|---|---|-----|-----|-----|----------------------|-----|-----|-----|--|--|
| 13 Cancer patients on the 62 day pathway breached 104 days at the end of November across six tumour sites. | | significant concern across UHL and isgiven the highest priority by the executive and operational | e patients breaching 104 days by month for 15-16: | | | | | | | | | | |
| Tumour site | Number of patients | teams . Since September, there have been weekly meetings chaired by the Chief Operating Officer, attended by the CMG Heads of Ops, | | Apr | Мау | Jun | Jul | Aug | Sep | Oct | Nov | | |
| Lung | breaching 104 days 1 | where they are required to account for their tumour site performance. | Patients breaching 104 days | 12 | 10 | 12 | 20 | 12 | 13 | 17 | 13 | | |
| Lower GI | 3 | | NB: not all patients confirmed Cancer | | | | | | | | | | |
| Upper GI | 2 | The number of patients breaching 104 days on a | - | | | | | | | | | | |
| HPB | 1 | 62 day pathway has dropped by four since the | | | | | | | | | | | |
| Urology | 5 | end of October. | | | | | | | | | | | |
| Haematology | 1 | | | | | | | | | | | | |
| The following factoristic contributed to delay | | band 7 Cancer Delivery Managers has been identified to support them. All three are now in post and they will jointly report to the Cancer | 5 | | | | | | | | | | |
| Complex case | 2 | Centre and the CMG management teams. This | | | | | | | | N N | | | |
| Patient initiated de | , | dedicated full-time service management will | horis water with with weeks seals out houts | | | | | | | | | | |
| Endoscopy delays | | improve Cancer performance over the medium term. | NPL oll notion to broaching 104 days underge a farmed therm | | | | | | | | | | |
| Complex diagnos pathway | tic 2 | | | IB: all patients breaching 104 days undergo a formal 'harm eview' process and these are reviewed by commissioners | | | | | | | | | |
| Tertiary referral | 1 | In light of poor performance against the 62 day | | | | | | | | | | | |
| Appointment dela | - | pathway, local commissioners have requested a remedial action plan for Cancer, which will be | | | | | | | | | | | |
| Repeat diagnostic required | | monitored through the Contract Performance Meetings. The plan is based around emerging | | et | N/A | | | | | | | | |
| | | themes from the first four months' of 62 day breach analysis and will aim to resolve known | standard / N/A | | | | | | | | | | |
| | delays in Cancer pathways. Undoub collective piece of work will impact po the number of patients breaching 104 da | | Revised date | | | | | | | | | | |
| | | | Lead Dired / Lead Off | | | | | Chief (linical L | | | | | |